Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:BMRN 19 December 2025 - 22 December 2025

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025)

BioMarin shares fell 3.5% to $58.98 on Dec. 22 after analysts weighed in on its $4.8 billion Amicus Therapeutics acquisition and the company confirmed it ended development of BMN 349. Truist Securities raised its price target to $100, citing strategic fit, while other analysts questioned the deal’s impact on growth and balance sheet risk.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

BioMarin agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at $4.8 billion. FOLD traded near $14.22 on December 22, reflecting market expectations for deal completion and timing. The transaction is expected to close in Q2 2026, pending regulatory and shareholder approvals. Either party may terminate if not closed by June 19, 2026, with a $175 million breakup fee.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock News Today: BioMarin’s $14.50 Buyout, Fresh Analyst Forecasts, and Key Dates to Watch (Dec. 22, 2025)

Amicus Therapeutics shares traded near $14.18 on Dec. 22, 2025, following BioMarin Pharmaceutical’s agreement to acquire the company for $14.50 per share in cash. Both boards have approved the $4.8 billion deal, with closing expected in Q2 2026 pending regulatory and shareholder approval. The narrow price spread reflects typical merger-arbitrage dynamics. Citigroup reaffirmed a Neutral rating and set a $14.50 target.
22 December 2025
···
Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

Amicus Therapeutics (FOLD) Stock on Dec. 22, 2025: BioMarin’s $14.50 Buyout, Latest News, Analyst Forecasts, and What’s Next

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at about $4.8 billion. Amicus shares traded at $14.18 on Dec. 22, reflecting market focus on deal completion. TD Cowen downgraded Amicus to Hold, setting a $14.50 target. The deal is expected to close in Q2 2026, pending approvals.
22 December 2025
··
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

BioMarin Pharmaceutical agreed Friday to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the company at $4.8 billion. FOLD shares closed near $14.18 after jumping 30% on the news. The deal is expected to close in Q2 2026, pending shareholder and regulatory approvals. Amicus disclosed a $175 million breakup fee and a June 19, 2026 outside date.
22 December 2025
····
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin shares jumped 17.7% to $61.15 on December 19 after announcing a $4.8 billion all-cash deal to acquire Amicus Therapeutics for $14.50 per share, a 33% premium. Trading volume hit 18.5 million shares. The acquisition, expected to close in Q2 2026, adds two marketed rare-disease drugs and a late-stage asset to BioMarin’s portfolio.
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

BioMarin Pharmaceutical will acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus stock closed at $14.18 on December 19, up 30% in a day and near the offer price. The deal is expected to close in Q2 2026, pending regulatory and shareholder approval. Amicus resolved key Galafold patent litigation ahead of the announcement.
21 December 2025
···
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks

BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion on Dec. 19, paying a 33% premium and adding two rare-disease drugs with $599 million in combined annual sales. The deal, plus an FDA approval for Cytokinetics and new IPO filings, drove biotech stocks higher ahead of the Christmas-shortened trading week. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·····
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at $4.8 billion. Amicus closed at $14.20 on Dec. 19, just below the buyout price. The deal, approved by both boards, is expected to close in Q2 2026 pending regulatory and shareholder approval. BioMarin plans to fund the purchase with cash and about $3.7 billion in new debt.
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at $4.8 billion, offering $14.50 per share. Amicus stock surged about 30% after the Dec. 19 announcement, trading near $14.18 as of Dec. 20. The deal awaits regulatory and shareholder approval, with closing expected in Q2 2026. Trading volume spiked as investors focused on merger risk and timing.
21 December 2025
··
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

BioMarin Pharmaceutical will acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus shares closed at $14.18 on December 19, reflecting a small merger spread tied to regulatory and deal-closing risks. Both boards approved the agreement. Closing is targeted for Q2 2026, pending shareholder and antitrust approvals.
20 December 2025
···
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin shares jumped 17.7% to $61.15 Friday after announcing a $4.8 billion all-cash deal to acquire Amicus Therapeutics at $14.50 per share. The acquisition adds two marketed rare-disease drugs and a Phase 3 asset, and resolves U.S. patent litigation over Galafold, delaying generic entry to 2037. BioMarin expects the deal to close in Q2 2026 and be accretive to earnings within a year.
20 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, offering $14.50 per share. Amicus stock jumped roughly 30% to $14.18 on heavy volume, trading just below the bid as investors assess deal closure risks. Both boards approved the transaction, with closing targeted for Q2 2026 pending shareholder and regulatory approvals.
20 December 2025
·····
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

BioMarin Pharmaceutical announced a $14.50-per-share all-cash deal to acquire Amicus Therapeutics, valuing the company at about $4.8 billion. Amicus shares jumped 30% to $14.18 following the news, trading just below the offer price. The deal is expected to close in the second quarter of 2026, pending regulatory and shareholder approval.
20 December 2025
··
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing the deal at about $4.8 billion. Amicus stock jumped roughly 30% Friday, closing near $14.18. Both boards approved the transaction, expected to close in Q2 2026. The offer is not subject to financing conditions.
20 December 2025
··
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical will acquire Amicus Therapeutics in an all-cash deal valued at about $4.8 billion, paying $14.50 per share—a 33% premium to Amicus’ prior close. The transaction, approved by both boards, is expected to close in Q2 2026 pending shareholder and regulatory approvals. BioMarin will fund the deal with cash and $3.7 billion in debt financing. The acquisition adds two rare-disease drugs and a Phase 3 pipeline asset.
19 December 2025
····

Stock Market Today

  • Oil above $90: Growth Outlook Brightens for EOG Resources amid Middle East Tensions
    April 9, 2026, 1:01 PM EDT. West Texas Intermediate crude oil prices have surpassed $95 per barrel due to rising tensions in the Middle East, boosting prospects for leading oil producer EOG Resources Inc. EOG's multi-basin portfolio, including the Permian Basin and Eagle Ford shale, positions it well to benefit from sustained high oil prices. The U.S. Energy Information Administration anticipates continued elevated prices, supporting strong cash flow generation for EOG and its shareholders. Similarly, ConocoPhillips and Exxon Mobil, with extensive upstream operations in low-cost drilling regions, stand to gain. Over the past year, EOG shares rose 32.9%, trading at a below-industry average price-to-EBITDA multiple of 6.92, with recent earnings estimate upgrades. EOG holds a neutral Zacks Rank #3 (Hold), signalling cautious optimism amid favorable market conditions.

Latest article

Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal

Unilever Snaps Up Grüns to Deepen U.S. Wellness Push After McCormick Food Deal

9 April 2026
Unilever said Thursday it will acquire U.S. greens-supplement brand Grüns for an undisclosed sum, with the deal expected to close later this year pending approvals. Grüns was valued at about $500 million in a 2025 Series B round, according to Reuters. The purchase follows Unilever’s recent agreement to combine its food business with McCormick.
Lumentum Stock Nears $960 After JPMorgan, Mizuho Raise Targets on Nvidia AI Optics Demand

Lumentum Stock Nears $960 After JPMorgan, Mizuho Raise Targets on Nvidia AI Optics Demand

9 April 2026
Lumentum shares climbed Thursday after JPMorgan raised its price target to $950, following Mizuho’s hike to $930. The moves come after Nvidia agreed last month to invest $2 billion in Lumentum and make multibillion-dollar purchase commitments. Lumentum reported February quarter revenue of $665.5 million, up 65.5% year-over-year. An SEC filing showed Lumentum will swap 5.7 million shares for $474.6 million in convertible notes.
SBTi Says Corporate Climate Targets Jumped 40% in 2025 as Asia Closes In on Europe

SBTi Says Corporate Climate Targets Jumped 40% in 2025 as Asia Closes In on Europe

9 April 2026
The number of companies with Science Based Targets initiative-validated climate goals reached 9,764 by the end of 2025, up 40% from the previous year. Asia added 1,216 companies, nearly matching Europe’s increase. Europe held 49% of validated targets, Asia 36%, and North America 11%. Japan led single markets with 2,091 companies.
Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
Go toTop